Abionic Company Profile

20:09 EDT 24th June 2018 | BioPortfolio

Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses the most advanced technology to supply physicians with a novel diagnostic tool and thereby provide patients with personal allergy profiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.

Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.

Abionic SA is a privately held high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab. The company also benefits from coaching of Genilem, the A3 Angels mentoring program and the CTI coaching.

Abionic was founded in 2010 by former scientists of the biomedical optics laboratory (LOB) at EPFL. The headquarters are located in Lausanne, Switzerland.


c/o EPFL - STI - LOB - BM4247
Station 17


Phone: +41 79 753 57 66
Fax: +41 21 693 78 20

News Articles [4 Associated News Articles listed on BioPortfolio]

Funding round pulls in $21.1M for Abionic

A round of Series C financing was closed by Abionic, bringing in $21.1 million in proceeds that will be used for the expansio -More- 

Abionic secures funding to expand portfolio of point-of-care IVD tests

Abionic has raised CHF20m ($21m) series C financing to expand its portfolio of point-of-care IVD tests for critical care and emergency medicine.

Abionic Successfully Raises CHF20 Million in Series C Financing

Network of Eminent High Net Worth Individuals Join Financing Syndicate Financing to Extend Abionic’s Portfolio of Point-of-Care IVD Tests for Critical ...

QUT to put grass pollen research to Swiss nanotech

(Queensland University of Technology) Queensland University of Technology (QUT) in Brisbane, Australia, and Swiss medtech company Abionic SA are collaborating to develop rapid, targeted tests for alle...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]


Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abi...

Abionic SA

Abionic has developed and commercialized abioSCOPE, a rapid point of care diagnostic platform to improve medical diagnosis. This revolutionary nano-technology-based test system pr...

More Information about "Abionic" on BioPortfolio

We have published hundreds of Abionic news stories on BioPortfolio along with dozens of Abionic Clinical Trials and PubMed Articles about Abionic for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Abionic Companies in our database. You can also find out about relevant Abionic Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Corporate Database Quicklinks

Searches Linking to this Company Record